The Food and Drug Administration (FDA) has approved PARI’s eRapid Nebulizer System (eRapid), the first electronic nebulizer to deliver Pulmozyme (dornase alfa [recombinant human DNase]; Genentech) for ...
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "PULMOZYME Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive ...
DUBLIN--(BUSINESS WIRE)--The "Pulmozyme" report has been added to ResearchAndMarkets.com's offering. Developed by Genentech, Pulmozyme is a recombinant form of human deoxyribonuclease I produced by ...
RICHMOND, Va., Jan. 26, 2015 /PRNewswire/ -- The eRapid Nebulizer System (eRapid) from PARI has been approved as the first electronic nebulizer by the Food and Drug Administration to deliver Genentech ...
(From insert) Daily administration of Pulmozyme Inhalation Solution in conjunction with standard therapies is indicated in the management of cystic fibrosis patients to improve pulmonary function. In ...
The US Food and Drug Administration (FDA) has approved the eRapid nebulizer system (PARI), the first electronic nebulizer to deliver dornase alfa (Pulmozyme, Genentech) for the treatment of cystic ...
Researchers from University College London (UCL), UCL Hospital (UCLH) and the Francis Crick Institute have revealed that a common drug used to treat cystic fibrosis has been shown to improve outcomes ...
Cystic fibrosis (CF) is a recessive genetic disease caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR). CFTR regulates ion transport across the lung epithelia, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results